Ceftriaxone Market Size Worth USD 2.2 billion by 2031, Expanding at a CAGR of 2.9%

In the field of medicine, the treatment of bacterial infections is of utmost importance. One such antibiotic that has gained significant attention is Ceftriaxone. Ceftriaxone is a broad-spectrum antibiotic belonging to the cephalosporin class. It is widely used in the treatment of various infections, including urinary tract infections, intra-abdominal infections, endocarditis, acute bacterial otitis media, meningitis, pneumonia, and others. This article aims to provide a comprehensive analysis of the Ceftriaxone market, including its global industry analysis, size, share, growth, trends, and forecast for the period 2022-2031.

Download sample PDF Brochure at: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85274

Valuation and Growth:

The global ceftriaxone market was valued at US$ 1.7 billion in 2021 and is projected to grow at a CAGR of 2.9% from 2022 to 2031, reaching over US$ 2.2 billion by 2031.

Analysts' Viewpoint:

Usage and Demand: Ceftriaxone is widely used across various indications including urinary tract infections, intra-abdominal infections, endocarditis, etc. Both generic and branded versions are driving the market, with off-label usage in several indications.

Market Expansion Opportunities: The availability of cost-effective generic versions, especially in developing countries, presents significant opportunities for market growth.

Market Dynamics:

Regional Demand: Demand for ceftriaxone injections is rising in countries like China and India due to increasing incidence rates of chronic diseases and the need for effective treatment options.Indication-wise Demand: Urinary tract infections account for a significant market share, with increasing preference for ceftriaxone, especially in developing countries.

Factors Driving Market Growth:

Increase in Chronic Diseases: The rising burden of chronic diseases globally, including urinary tract infections, is a major driver of ceftriaxone demand.Growing Geriatric Population: The increase in the elderly population, especially in developed countries, contributes to higher demand for ceftriaxone due to the prevalence of bacterial infections in this demographic.

Market Segmentation

The Ceftriaxone market can be segmented based on indication, route of administration, distribution channel, and geography.

Indication

Ceftriaxone is indicated for the treatment of various infections, including:

Urinary Tract Infections (UTIs)

Intra-abdominal Infections

Endocarditis

Acute Bacterial Otitis Media

Meningitis

Pneumonia

Others

Place an Order Copy of Ceftriaxone Market Report at: https://www.transparencymarketresearch.com/checkout.php?rep_id=85274<ype=S

Route of Administration

Ceftriaxone can be administered via the following routes:

Intravenous (IV)

Intramuscular (IM)

Distribution Channel

Ceftriaxone is available through various distribution channels, including:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Geography

The Ceftriaxone market is analyzed across the following regions:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Market Dynamics
Drivers
Increasing prevalence of bacterial infections
Rising demand for effective antibiotics
Growing awareness about the benefits of Ceftriaxone
Technological advancements in drug delivery systems

Restraints
Development of antibiotic resistance
Side effects associated with Ceftriaxone
Stringent regulatory guideline

Analysis of Key Players:
Market Fragmentation: The market is fragmented with numerous players investing in research and development, primarily to introduce generic ceftriaxone variants.
Key Players: Prominent players include Hikma Pharmaceuticals, Qilu Pharmaceutical, Novartis AG, Baxter International, among others.

Key Developments:
Government Regulations: Instances like India imposing anti-dumping duty on ceftriaxone raw materials from China affect market dynamics.
Initiatives: Launch of initiatives like Novartis' COVID-19 Portfolio, including ceftriaxone, to address major symptoms of the disease in low-income countries.

More Trending Reports by Transparency Market Research -

Epilepsy Therapeutics Market

https://www.globenewswire.com/en/news-release/2022/08/16/2499081/0/en/Epilepsy-Therapeutics-Market-to-Exceed-Value-of-US-14-9-Bn-by-2031-observes-TMR-Study.html

Weight Management Market

https://www.globenewswire.com/en/news-release/2022/08/10/2496053/0/en/Weight-Management-Market-Size-Worth-US-11-1-Bn-by-2030-Transparency-Market-Research.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.